Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Desensitization and Tachyphylaxis01:20

Desensitization and Tachyphylaxis

2.9K
Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
2.9K
Preventive Healthcare Services01:30

Preventive Healthcare Services

1.7K
Preventive healthcare services keep people healthy via frequent check-ups, screening, and counseling. They primarily aid in disease prevention rather than treating an acute or chronic illness. Preventive treatment also keeps individuals productive and energetic, allowing them to work well into their retirement years. Examples of preventive care services include:
1.7K
Transmission-based Precautions II: Airborne and Protective Environment01:25

Transmission-based Precautions II: Airborne and Protective Environment

1.8K
Transmission-based precautions are for patients infected or suspected to be infected (or colonized) with organisms posing a significant risk to others. The transmission precautions include airborne and protective environment precautions.
Airborne precautions:
Use airborne precautions when treating patients known or suspected to have diseases that spread through the air—for example, tuberculosis or measles. These organisms are present in smaller droplets expelled by an infected person and...
1.8K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

945
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
945
Vaccinations01:51

Vaccinations

50.8K
Overview
50.8K
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

827
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
827

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mim8 Bispecific Antibody Prophylaxis in Hemophilia A with or without Inhibitors.

The New England journal of medicine·2026
Same author

Implementing Shared Decision-Making in Haemophilia Care: Best Practice Recommendations From a Western European Multi-Stakeholder Delphi Process.

Haemophilia : the official journal of the World Federation of Hemophilia·2026
Same author

Is marstacimab the next step in personalized and effective haemophilia management?

Expert review of clinical pharmacology·2026
Same author

A revised classification of FVIII concentrates: rationale and novel metrics.

Blood advances·2026
Same author

Concizumab in hemophilia with inhibitors: longer-term efficacy and safety results from the phase 3 explorer7 study.

Blood advances·2026
Same author

Efficacy and safety of marstacimab prophylaxis in hemophilia A/B with inhibitors: results from the phase 3 BASIS trial.

Blood·2025
Same journal

Prophylactic Factor Replacement Versus on-Demand Factor Replacement Following Primary Total Knee Arthroplasty in Patients With Hemophilia: A Retrospective Study With an Average 10-Year Follow-up.

Haemophilia : the official journal of the World Federation of Hemophilia·2026
Same journal

Accuracy of Factor VIII Assays for Measuring Damoctocog Alfa Pegol: A Comparative Analysis.

Haemophilia : the official journal of the World Federation of Hemophilia·2026
Same journal

Real-World Assessment of rVIII-SingleChain for Prophylactic Treatment in People With Severe Hemophilia A in High-Resource Settings.

Haemophilia : the official journal of the World Federation of Hemophilia·2026
Same journal

Platelet Hyperreactivity May Contribute to Thrombotic Complications in Afibrinogenemia: A Case-Based Observation.

Haemophilia : the official journal of the World Federation of Hemophilia·2026
Same journal

Predictors and Clinical Impact of Time to Diagnosis in Acquired Haemophilia A: An 11-Year Retrospective Cohort Study.

Haemophilia : the official journal of the World Federation of Hemophilia·2026
Same journal

Clinical Outcomes of Efanesoctocog Alfa Prophylaxis in Children With Severe Haemophilia A: Interim Data From XTEND-ed.

Haemophilia : the official journal of the World Federation of Hemophilia·2026
See all related articles

Related Experiment Video

Updated: Dec 20, 2025

Fabrication of Pulsatile Polymeric Microparticles Encapsulating Rabies Antigen
07:44

Fabrication of Pulsatile Polymeric Microparticles Encapsulating Rabies Antigen

Published on: May 12, 2023

1.5K

Redefining prophylaxis in the modern era.

Johnny N Mahlangu1, Victor Blanchette2, Robert Klamroth3

  • 1Faculty of Health Sciences, Haemophilia Comprehensive Care, Charlotte Maxeke Johannesburg Academic Hospital, University of the Witwatersrand and the NHLS, Johannesburg, South Africa.

Haemophilia : the Official Journal of the World Federation of Hemophilia
|May 30, 2020
PubMed
Summary
This summary is machine-generated.

Prophylaxis is the standard of care for haemophilia, offering benefits like reduced bleeds and improved quality of life. Evolving therapies necessitate redefining prophylaxis targets for better outcomes.

Keywords:
modern eranovel therapiesprophylaxisredefinitionsteady-statetrough levels

More Related Videos

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

15.4K
Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens
13:47

Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens

Published on: May 19, 2020

3.7K

Related Experiment Videos

Last Updated: Dec 20, 2025

Fabrication of Pulsatile Polymeric Microparticles Encapsulating Rabies Antigen
07:44

Fabrication of Pulsatile Polymeric Microparticles Encapsulating Rabies Antigen

Published on: May 12, 2023

1.5K
Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

15.4K
Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens
13:47

Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens

Published on: May 19, 2020

3.7K

Area of Science:

  • Hematology
  • Bleeding Disorders
  • Pharmacology

Background:

  • Prophylaxis is the global standard of care for hemophilia, superior to episodic treatment.
  • Key benefits include reduced bleeding, fewer musculoskeletal issues, and enhanced quality of life.
  • Novel therapies are transforming hemophilia management, necessitating updated prophylaxis strategies.

Purpose of the Study:

  • To redefine prophylaxis in the modern era of hemophilia treatment.
  • To present data supporting higher trough levels for effective prophylaxis.
  • To introduce steady-state hemostasis as a potential new prophylaxis target.

Main Methods:

  • State-of-the-art review of current hemophilia prophylaxis.
  • Analysis of data supporting revised prophylaxis targets.
  • Exploration of steady-state hemostasis as a novel therapeutic goal.

Main Results:

  • Current prophylaxis offers significant advantages over episodic treatment.
  • Higher trough levels are supported by emerging data for improved prophylaxis.
  • Steady-state hemostasis presents a promising new target for hemophilia management.

Conclusions:

  • Redefining prophylaxis is crucial in light of advancements in hemophilia therapy.
  • Achieving higher trough levels and steady-state hemostasis can optimize prophylaxis.
  • These redefined targets promise improved outcomes for individuals with hemophilia.